Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab plus Ipilimumab in Advanced Neuroendocrine Tumors
NCT03420521Phase 2Terminated
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Mar 2018
- Primary completion
- Nov 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab, ipilimumab in neuroendocrine tumors (NETs), sponsored by Sidney Kimmel Comprehensive Cancer Center. Started Mar 2018; status: terminated.
02
Drugs
nivolumabipilimumab
03
Conditions
neuroendocrine tumors (NETs)
Beyond the preview
Go deeper on NCT03420521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03420521.